Monte Rosa Therapeutics GLUE
NASDAQ GLUE
$10.31 -0.19 (-1.81%)
At close: Nov 11, 2026 · 4:00 PM EST

Monte Rosa Therapeutics (GLUE) Gains (Losses) on Sale of Assets & Investments (2022 - 2025)

Updated

Monte Rosa Therapeutics (GLUE) reported Non Operating Investment Income of $59,000 for FY2025.

Analysis

Monte Rosa Therapeutics (GLUE) Gains (Losses) on Sale of Assets & Investments (2022 - 2025) Analysis & Trends

  • Non Operating Investment Income has a three-year compound annual growth rate of -18.5% (FY2022 to FY2025).
  • The FY2025 figure ranks as the highest annual Non Operating Investment Income since FY2022.
  • According to Business Quant data, Non Operating Investment Income came in at $24,000 in FY2023 (-78.0%) and $109,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Monte Rosa Therapeutics 897.23 Mn 472.20 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 59,000.00
Jun 30, 2023 24,000.00
Mar 31, 2023 -131,000.00
Sep 30, 2022 -16,000.00
Mar 31, 2022 125,000.00
API Access

Monte Rosa Therapeutics Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=GLUE&period=max&api_key=YOUR_API_KEY